Ginkgo Bioworks enters $100M at-the-market equity sales agreement with Allen & Company

Ginkgo Bioworks Holdings, Inc.

Up to $100M in Class A common stock may be sold through Agent Allen & Company.
Agent receives commission of up to 3% of gross proceeds from each sale.
Registration statement on Form S-3 declared effective August 14, 2025; prospectus supplement dated Sept 4, 2025.
Net proceeds to be used for general corporate purposes including operations, tech development, working capital.
Company may terminate Sales Agreement with sufficient written notice; no assurance any shares will be issued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.